头颈癌患者免疫检查点阻断后严重免疫相关不良事件的系统综述
该系统综述检索MEDLINE、EMBASE等数据库,纳入11项研究,分析头颈癌患者接受免疫检查点抑制剂后的治疗相关不良事件。从791例患者中识别46例治疗相关不良事件,至少12例可能与irAEs相关,8例严重irAEs来自个案报告;PD-1抑制剂最常见累及内分泌、皮肤和胃肠道系统。
要点
- 头颈癌患者接受免疫检查点抑制剂后,PD-1抑制剂相关不良事件常见于内分泌、皮肤和胃肠道系统。
- 严重irAEs的识别主要来自个案报告和病例系列,需提高警惕。
- 需纵向研究以制定irAEs的早期识别和管理策略。
核心结论
- 头颈癌患者接受免疫检查点阻断后可发生严重免疫相关不良事件,需快速识别和及时治疗。
研究设计与样本
- 系统综述检索MEDLINE、EMBASE、Web of Science、PubMed和Cochrane CENTRAL数据库的英文文献。
- 从1715篇文献中纳入11项研究,涉及791例接受免疫检查点抑制剂治疗的头颈癌患者。
主要发现
- 8例严重irAEs来自个案报告和病例系列。
- 共识别46例治疗相关不良事件,其中至少12例可能与irAEs相关。
- 接受PD-1抑制剂的患者中最常见的不良事件涉及内分泌、皮肤和胃肠道系统。
临床怎么用
- 临床应提高对头颈癌患者免疫检查点抑制剂相关irAEs的识别意识,及时处理可疑症状。
局限性
- 严重irAEs数据主要来自个案报告和病例系列,缺乏纵向研究证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors confer significant clinical benefit by bolstering immune-system activity, however, they also produce a spectrum of immune-related adverse events (irAEs). Rapid recognition and timely treatment of these patients is essential for improved outcomes. METHODS: We conducted a systematic review of English-language articles in MEDLINE, EMBASE, Web of Science, PubMed, and Cochrane CENTRAL databases on patients with head and neck cancer treated with immune checkpoint inhibitors who developed treatment-related adverse events. RESULTS: Of 1715 unique citations, 11 studies met inclusion criteria. Eight patients with serious irAEs were reported from case reports and case series. Overall, 46 treatment-related AEs were identified from the pooled 791 patients with at least 12 having potential relevance to irAEs. The most frequent AEs observed in patients receiving PD-1 inhibitors involved the endocrine, cutaneous, and gastrointestinal systems. CONCLUSIONS: Characterizing irAEs in longitudinal studies is needed for developing strategies for their prompt recognition and management.
引用
- Shah M, Jomaa MK, Ferrarotto R, et al. Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head Neck. 2019. PMID: 31414560. doi:10.1002/hed.25911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。